請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17757
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 呂紹俊 | |
dc.contributor.author | Ying-Chen Yu | en |
dc.contributor.author | 游盈甄 | zh_TW |
dc.date.accessioned | 2021-06-08T00:43:05Z | - |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-13 | |
dc.identifier.citation | Abifadel, M., Varret, M., Rabes, J.P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34, 154-156.
Abramson, S., Korchak, H., Ludewig, R., Edelson, H., Haines, K., Levin, R.I., Herman, R., Rider, L., Kimmel, S., and Weissmann, G. (1985). Modes of action of aspirin-like drugs. Proc Natl Acad Sci U S A 82, 7227-7231. Akira, S. (2001). Toll-like receptors and innate immunity. Adv Immunol 78, 1-56. Anstee, Q.M., Targher, G., and Day, C.P. (2013). Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10, 330-344. Antithrombotic Trialists, C., Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., Kearney, P. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860. Assy, N., Hussein, O., Khalil, A., Luder, A., Szvalb, S., Paizi, M., and Spira, G. (2007). The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci 52, 1187-1193. Brown, M.S., and Goldstein, J.L. (1984). How LDL receptors influence cholesterol and atherosclerosis. Sci Am 251, 58-66. Browning, J.D., and Horton, J.D. (2004). Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114, 147-152. Brusq, J.M., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., and Issandou, M. (2006). Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47, 1281-1288. Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., and Shoelson, S.E. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11, 183-190. Chang, P.Y., Chen, Y.J., Chang, F.H., Lu, J., Huang, W.H., Yang, T.C., Lee, Y.T., Chang, S.F., Lu, S.C., and Chen, C.H. (2013). Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res 99, 137-145. Chang, X., Yan, H., Fei, J., Jiang, M., Zhu, H., Lu, D., and Gao, X. (2010). Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 51, 2504-2515. Chen, W., Miao, Y.Q., Fan, D.J., Yang, S.S., Lin, X., Meng, L.K., and Tang, X. (2011). Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech 12, 705-711. Cheng, Z., Pang, T., Gu, M., Gao, A.H., Xie, C.M., Li, J.Y., Nan, F.J., and Li, J. (2006). Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta 1760, 1682-1689. Daugherty, A., Zweifel, B.S., Sobel, B.E., and Schonfeld, G. (1988). Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 8, 768-777. Day, C.P., and James, O.F. (1998). Steatohepatitis: a tale of two 'hits'? Gastroenterology 114, 842-845. Dong, B., Li, H., Singh, A.B., Cao, A., and Liu, J. (2015). Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem 290, 4047-4058. Dong, B., Wu, M., Li, H., Kraemer, F.B., Adeli, K., Seidah, N.G., Park, S.W., and Liu, J. (2010). Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 51, 1486-1495. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., and Parks, E.J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351. Dumas, M.E., Barton, R.H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J.C., et al. (2006). Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 103, 12511-12516. Endo, H., Hosono, K., Inamori, M., Kato, S., Nozaki, Y., Yoneda, K., Akiyama, T., Fujita, K., Takahashi, H., Yoneda, M. (2009). Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 79, 44-51. Enjoji, M., and Nakamuta, M. (2010). Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World J Gastroenterol 16, 800-803. Esterbauer, H., Schaur, R.J., and Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128. Fabbrini, E., Mohammed, B.S., Magkos, F., Korenblat, K.M., Patterson, B.W., and Klein, S. (2008). Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424-431. Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112. Farrell, G.C., van Rooyen, D., Gan, L., and Chitturi, S. (2012). NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver 6, 149-171. Farrell, G.C., Wong, V.W., and Chitturi, S. (2013). NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol 10, 307-318. Febbraio, M., Hajjar, D.P., and Silverstein, R.L. (2001). CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108, 785-791. Forsyth, B.W., Horwitz, R.I., Acampora, D., Shapiro, E.D., Viscoli, C.M., Feinstein, A.R., Henner, R., Holabird, N.B., Jones, B.A., Karabelas, A.D. (1989). New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA 261, 2517-2524. Goldstein, J.L., and Brown, M.S. (1977). The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46, 897-930. Goulinet, S., and Chapman, M.J. (1993). Plasma lipoproteins in the golden Syrian hamster (Mesocricetus auratus): heterogeneity of apoB- and apoA-I-containing particles. J Lipid Res 34, 943-959. Gu, L., Li, N., Gong, J., Li, Q., Zhu, W., and Li, J. (2011). Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis 203, 1602-1612. Guan, S., Wang, B., Li, W., Guan, J., and Fang, X. (2010). Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 38, 1161-1169. Harrison, S.A., Torgerson, S., and Hayashi, P.H. (2003). The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98, 2042-2047. Hawkey, C.J. (2001). COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 15, 801-820. Horton, J.D., Cuthbert, J.A., and Spady, D.K. (1995). Regulation of hepatic 7 alpha-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem 270, 5381-5387. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91. Huang, Z., Cai, X., Li, S., Zhou, H., Chu, M., Shan, P., and Huang, W. (2013). Berberineattenuated monocyte adhesion to endothelial cells induced by oxidized lowdensity lipoprotein via inhibition of adhesion molecule expression. Mol Med Rep 7, 461-465. Huang, Z., Dong, F., Li, S., Chu, M., Zhou, H., Lu, Z., and Huang, W. (2012a). Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 690, 164-169. Huang, Z., Meng, S., Wang, L., Wang, Y., Chen, T., and Wang, C. (2012b). Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-kappaB activation in human THP-1 macrophages. Anat Rec (Hoboken) 295, 78-86. Hubscher, S.G. (2006). Histological assessment of non-alcoholic fatty liver disease. Histopathology 49, 450-465. Hundal, R.S., Petersen, K.F., Mayerson, A.B., Randhawa, P.S., Inzucchi, S., Shoelson, S.E., and Shulman, G.I. (2002). Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109, 1321-1326. Ioannou, G.N., Morrow, O.B., Connole, M.L., and Lee, S.P. (2009). Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 50, 175-184. Kang, L.I., Mars, W.M., and Michalopoulos, G.K. (2012). Signals and cells involved in regulating liver regeneration. Cells 1, 1261-1292. Kim, D., Kim, W.R., Kim, H.J., and Therneau, T.M. (2013). Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57, 1357-1365. Kopp, E., and Ghosh, S. (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265, 956-959. Krieger, M. (1999). Charting the fate of the 'good cholesterol': identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 68, 523-558. Lagace, T.A., Curtis, D.E., Garuti, R., McNutt, M.C., Park, S.W., Prather, H.B., Anderson, N.N., Ho, Y.K., Hammer, R.E., and Horton, J.D. (2006). Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116, 2995-3005. Lee, Y.S., Kim, W.S., Kim, K.H., Yoon, M.J., Cho, H.J., Shen, Y., Ye, J.M., Lee, C.H., Oh, W.K., Kim, C.T. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55, 2256-2264. Levene, A.P., and Goldin, R.D. (2012). The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152. Ley, R.E., Peterson, D.A., and Gordon, J.I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837-848. Lin, H.L., Yen, H.W., Hsieh, S.L., An, L.M., and Shen, K.P. (2014). Low-dose aspirin ameliorated hyperlipidemia, adhesion molecule, and chemokine production induced by high-fat diet in Sprague-Dawley rats. Drug Dev Res 75, 97-106. Liu, Y., Zhang, L., Song, H., and Ji, G. (2013). Update on berberine in nonalcoholic Fatty liver disease. Evid Based Complement Alternat Med 2013, 308134. Lukacs, N.W., Strieter, R.M., Chensue, S.W., Widmer, M., and Kunkel, S.L. (1995). TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 154, 5411-5417. Lusis, A.J. (2000). Atherosclerosis. Nature 407, 233-241. Maheady, D.C. (1989). Reye's syndrome: review and update. J Pediatr Health Care 3, 246-250. Maher, J.J., Leon, P., and Ryan, J.C. (2008). Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology 48, 670-678. Malhi, H., and Gores, G.J. (2008). Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 28, 360-369. Marieb, E.N., and Hoehn, K. (2013). Human anatomy & physiology (10th ed.). Pearson, Upper Saddle River, 166-167. Mello, A.P., da Silva, I.T., Abdalla, D.S., and Damasceno, N.R. (2011). Electronegative low-density lipoprotein: origin and impact on health and disease. Atherosclerosis 215, 257-265. Musso, G., Cassader, M., and Gambino, R. (2011). Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 22, 489-496. Ogawa, T., Fujii, H., Yoshizato, K., and Kawada, N. (2010). A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol 177, 153-165. Oram, J.F., and Lawn, R.M. (2001). ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42, 1173-1179. Osborne, J.C., Jr., Bronzert, T.J., and Brewer, H.B., Jr. (1977). Self-association of apo-C-I from the human high density lipoprotein complex. J Biol Chem 252, 5756-5760. Pan, M.R., Chang, H.C., and Hung, W.C. (2008). Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal 20, 1134-1141. Qureshi, K., and Abrams, G.A. (2007). Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 13, 3540-3553. Seger, R., and Krebs, E.G. (1995). The MAPK signaling cascade. FASEB J 9, 726-735. Shen, H., Shahzad, G., Jawairia, M., Bostick, R.M., and Mustacchia, P. (2014). Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 40, 1066-1073. Shimpo, M., Ikeda, U., Maeda, Y., Ohya, K., Murakami, Y., and Shimada, K. (2000). Effects of aspirin-like drugs on nitric oxide synthesis in rat vascular smooth muscle cells. Hypertension 35, 1085-1091. Steinberg, D., and Witztum, J.L. (2010). Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 30, 2311-2316. Strauss, R.S., Barlow, S.E., and Dietz, W.H. (2000). Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. Journal of Pediatrics 136, 0727-0733. Streetz, K.L., Luedde, T., Manns, M.P., and Trautwein, C. (2000). Interleukin 6 and liver regeneration. Gut 47, 309-312. Subramanian, S., Goodspeed, L., Wang, S., Kim, J., Zeng, L., Ioannou, G.N., Haigh, W.G., Yeh, M.M., Kowdley, K.V., O'Brien, K.D. (2011). Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res 52, 1626-1635. Sun, X., Han, F., Yi, J., Han, L., and Wang, B. (2011). Effect of aspirin on the expression of hepatocyte NF-kappaB and serum TNF-alpha in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci 26, 765-770. Sun, X., Zhang, X., Hu, H., Lu, Y., Chen, J., Yasuda, K., and Wang, H. (2009). Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fibrosis. Biol Pharm Bull 32, 1533-1537. Sundaresan, S., Vijayagopal, P., Mills, N., Imrhan, V., and Prasad, C. (2011). A mouse model for nonalcoholic steatohepatitis. J Nutr Biochem 22, 979-984. Tannapfel, A., Denk, H., Dienes, H.P., Langner, C., Schirmacher, P., Trauner, M., and Flott-Rahmel, B. (2011). Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 458, 511-523. Timothy C. Birdsall, N.D.a.G.S.K., N.D. (1997). Berberine: Therapeutic Potential of an Alkaloid Found in Several Medicinal Plants. Alternative Medicine Review 2, 94-103. van Diepen, J.A., Vroegrijk, I.O., Berbee, J.F., Shoelson, S.E., Romijn, J.A., Havekes, L.M., Rensen, P.C., and Voshol, P.J. (2011). Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 301, E1099-1107. Van Rooyen, D.M., Gan, L.T., Yeh, M.M., Haigh, W.G., Larter, C.Z., Ioannou, G., Teoh, N.C., and Farrell, G.C. (2013). Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 59, 144-152. Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., and Szabo, G. (2009). VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49, 989-997. Videla, L.A., Tapia, G., Rodrigo, R., Pettinelli, P., Haim, D., Santibanez, C., Araya, A.V., Smok, G., Csendes, A., Gutierrez, L. (2009). Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) 17, 973-979. Vinals, M., Bermudez, I., Llaverias, G., Alegret, M., Sanchez, R.M., Vazquez-Carrera, M., and Laguna, J.C. (2005). Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 66, 141-149. Wang, Y., Jia, X., Ghanam, K., Beaurepaire, C., Zidichouski, J., and Miller, L. (2010). Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis 209, 111-117. Wang, Y.X., Kong, W.J., Li, Y.H., Tang, S., Li, Z., Li, Y.B., Shan, Y.Q., Bi, C.W., Jiang, J.D., and Song, D.Q. (2012). Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Bioorg Med Chem 20, 6552-6558. Wigg, A.J., Roberts-Thomson, I.C., Dymock, R.B., McCarthy, P.J., Grose, R.H., and Cummins, A.G. (2001). The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48, 206-211. Wouters, K., van Bilsen, M., van Gorp, P.J., Bieghs, V., Lutjohann, D., Kerksiek, A., Staels, B., Hofker, M.H., and Shiri-Sverdlov, R. (2010). Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 584, 1001-1005. Yang, Y., Qi, J., Wang, Q., Du, L., Zhou, Y., Yu, H., Kijlstra, A., and Yang, P. (2013). Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci 54, 2516-2522. Yimin, Furumaki, H., Matsuoka, S., Sakurai, T., Kohanawa, M., Zhao, S., Kuge, Y., Tamaki, N., and Chiba, H. (2012). A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein. Lab Invest 92, 265-281. Yin, J., Zhang, H., and Ye, J. (2008). Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 8, 99-111. Yin, M.J., Yamamoto, Y., and Gaynor, R.B. (1998). The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77-80. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17757 | - |
dc.description.abstract | 非酒精性脂肪肝 (Nonalcoholic fatty liver;NAFLD) 為最常見的慢性肝臟疾病。其病程有不同嚴重程度的發展,由單純的脂肪堆積,到較嚴重的非酒精性脂肪肝炎 (Nonalcoholic stetohepatitis;NASH)、肝纖維化,甚至到肝硬化。許多動物模式的研究也都指出飲食中脂肪,尤其是膽固醇,是肝臟從脂肪堆積演變成NASH的重要因素。而實驗室學長利用高脂高膽固醇飼料餵食倉鼠,建立了新的NASH動物模式。
黃連素 (Berberine;BBR) 是植物性生物鹼,已被證實可以藉由增加LDL受器蛋白表現量,進而降低血液中LDL-膽固醇,被認為是機轉不同於Statin類藥物的降血脂藥。阿斯匹靈 (Aspirin;ASA) 是非類固醇消炎藥的一種,報導指出可以改善肥胖大鼠的高血糖及血脂異常等症狀。我的實驗目的是要探討在倉鼠的NASH動物模式中,BBR及ASA是否能夠改善NASH的症狀。 首先,我們以高脂高膽固醇飼料餵食的倉鼠動物模式,評估ASA及BBR是否有抑制NASH的功效。倉鼠餵食一般chow diet或高脂高膽固醇的飼料 (HFC) 以及HFC添加ASA (HFC+ASA)或BBR (HFC+BBR),為期10週。結果顯示ASA及BBR兩者皆會降低血漿膽固醇、三酸甘油酯濃度以及ALT、AST活性。透過膠體過濾法分析,顯示HFC+ASA及HFC+BBR組的VLDL-、LDL-膽固醇含量都低於HFC組的倉鼠;肝臟病理切片分析,觀察到在HFC+ASA及HFC+BBR組的發炎程度也低於HFC組的倉鼠。本次實驗顯示降膽固醇藥以及抗發炎藥可以減緩NAFLD進展成NASH的程度。 由於實驗一的動物每組只有3隻,因此我們再進行一個動物實驗去驗證ASA及BBR抑制NAFLD進展成NASH的功效。在餵食6週後,結果顯示BBR仍然可降低血漿膽固醇、三酸甘油酯濃度以及ALT、AST活性。而ASA仍明顯降低ALT、AST活性,但並無降低血液膽固醇、三酸甘油酯濃度的作用。然而,ASA及BBR共同處理並沒有加成效果。不過仍然觀察到HFC+ASA及HFC+BBR的倉鼠,其肝臟發炎和纖維化程度都低於HFC組的倉鼠。除此之外,在免疫組織染色中觀察到,與HFC組倉鼠相比,HFC+ASA及HFC+BBR兩組NF-κB訊號都有明顯減少。本次實驗顯示ASA及BBR可以抑制NF-κB活化,另外BBR可以提高LDLR降低血液膽固醇,進而減輕倉鼠因高脂高膽固醇飼料而誘導的NASH。 | zh_TW |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. NAFLD has a wide histologic spectrum ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), to fibrosis and cirrhosis. Recent studies indicate that dietary lipid, especially cholesterol, is a critical factor of the development of NASH. An NASH animal model, by feeding golden Syrian hamster with high-fat/high-cholesterol (HFC) diet, is established in our laboratory.
Berberine (BBR) is a plant alkaloid, and has been demonstrated to lower cholesterol by increasing LDL-receptor; the mechanism of action is different from that of statins. Aspirin (ASA) is a nonsteroidal anti-inflammatory drug, has been reported to reverse hyperglycemia and dyslipidemia in obese rodents. In this study, we aim to test if BBR and ASA able to improve NASH in the hamster model. In the first animal experiment, golden Syrian hamsters were fed with chow diet, or high fat-cholesterol diet (HFC), HFC+ASA diet or HFC+BBR diet for 10 weeks. The results show that both ASA and BBR lower plasma levels of cholesterol, triglycerides, alanine aminotransferase (ALT), aspartate aminotransferase (AST). And gel-filtration analysis of the lipoprotein profile reveals that both ASA and BBR decrease cholesterol levels in VLDL and LDL fractions compared with that in the HFC-fed hamsters. Histopathological analyses of liver showing that hamsters treated with ASA and BBR have lower inflammation level than hamsters in the HFC group. Our results in this study suggest that cholesterol-lowering drug and anti-inflammatory drug may help to alleviate the severity of NASH in HFC fed hamsters. Because every experimental group has only 3 hamsters, we then carried out another animal experiment to evaluate the effects of ASA and BBR. In this study 6 hamsters in each group were fed the experimental diets for 6 weeks. The results show that BBR still lowers plasma levels of cholesterol, triglycerides, ALT and AST. And ASA lowers ALT, AST, but it has no effect on plasma levels of cholesterol and triglycerides. However, there is no additive effect in ASA+BBR group. The hamsters in HFC+ASA and HFC+BBR groups exhibit less hepatic inflammation and fibrosis than the hamsters in HFC group. Furthermore, immunohistochemistry stain showing that both ASA and BBR reduced hepatic NF-κB signals compared with that in HFC group. Our results in this study suggest that ASA and BB inhibited NF-κB activation and decreased plasma lipids and thus alleviate inflammation in HFC diet-induced NASH in hamsters. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T00:43:05Z (GMT). No. of bitstreams: 1 ntu-104-R02442029-1.pdf: 2119198 bytes, checksum: 03c68c5cae7ba764b92c4123af504722 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員審定書 I
誌謝 II 摘要 IV Abstract VI 目錄 VIII 圖表目錄 XI 第一章、緒論 1 第一節、文獻回顧 2 一、肝臟的結構與功能 2 二、非酒精性脂肪肝 (Nonalcoholic fatty liver disease, NAFLD) 5 三、非酒精性脂肪肝炎 (NASH) 與肝纖維化 6 四、膽固醇對NAFLD與NASH的影響 11 五、黃連素 (Berberine;BBR) 13 六、阿斯匹靈 (Aspirin; ASA) 15 第二節、研究動機與實驗目的 19 一、研究動機 19 二、實驗目的 19 第二章、材料與方法 20 第一節、實驗材料 21 第二節、動物實驗 22 一、動物模式 22 二、動物飼養、實驗設計、飼料製備、組織取樣及樣品前處理 22 三、血漿分析 25 四、肝臟三酸甘油酯、總膽固醇含量 31 五、糞便中膽固醇集中性固醇分析 31 六、分析肝臟中蛋白表現量 32 七、酵素連結免疫吸附法(Enzyme-Linked ImmunoSorbent Assay, ELISA) 35 八、肝臟纖維化病理分析 35 第三節、統計分析 37 第三章、實驗結果 38 第一節、動物實驗I - 飼養10週 39 第二節、動物實驗II - 飼養6週 43 第四章、討論 51 第一節、膽固醇誘導倉鼠產生NASH及肝纖維化 52 第二節、ASA與BBR對於降低膽固醇的效果 52 第三節、ASA與BBR具有減輕NASH及Fibrosis的功效 54 第四節、總結 57 第五章、圖表 58 參考文獻 78 | |
dc.language.iso | zh-TW | |
dc.title | 阿斯匹靈及黃連素減輕倉鼠因高脂高膽固醇飼料所引起的非酒精性脂肪肝炎 | zh_TW |
dc.title | Aspirin and berberine ameliorate high-fat/high-cholesterol diet induced Nonalcoholic Steatohepatitis (NASH) in hamsters | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃青真,張博淵,陳惠玲,吳文惠 | |
dc.subject.keyword | 非酒精性脂肪肝,非酒精性脂肪肝炎,阿斯匹靈,黃連素,NF-κB,膽固醇, | zh_TW |
dc.subject.keyword | NAFLD,NASH,Aspirin,Berberine,NF-κB,cholesterol, | en |
dc.relation.page | 92 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2015-08-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.07 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。